[go: up one dir, main page]

HK1056325A - Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders - Google Patents

Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders Download PDF

Info

Publication number
HK1056325A
HK1056325A HK03108713.6A HK03108713A HK1056325A HK 1056325 A HK1056325 A HK 1056325A HK 03108713 A HK03108713 A HK 03108713A HK 1056325 A HK1056325 A HK 1056325A
Authority
HK
Hong Kong
Prior art keywords
melagatran
medicament
manufacture
treatment
ischemic disorders
Prior art date
Application number
HK03108713.6A
Other languages
Chinese (zh)
Inventor
Gustafsson David
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1056325A publication Critical patent/HK1056325A/en

Links

HK03108713.6A 2000-11-06 2000-11-09 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders HK1056325A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US705912 2000-11-06

Publications (1)

Publication Number Publication Date
HK1056325A true HK1056325A (en) 2004-02-13

Family

ID=

Similar Documents

Publication Publication Date Title
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
AU2002222853A1 (en) Therapeutic compounds
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
AU2001286221A1 (en) Remedies for ischemic diseases
AU2002234525A1 (en) Transdermal therapeutic system comprising the active ingredient oxybutynin
TWI345975B (en) Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
AU6910600A (en) Methods for the treatment of mental disorders
AU2001258395A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
AU2001243515A1 (en) Combination drug therapy
AU2562501A (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
WO2002083083A3 (en) Pharmaceutically active compounds and methods of use
AU2002218750A1 (en) Photoactivated drug therapy
IL150403A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
AU8339301A (en) Compounds for the treatment of addictive disorders
HK1056325A (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
AU2002210286A1 (en) Medicine intended for treatment of multiple sclerosis
HUP0300876A3 (en) Use of diclofenac for the manufacture of medicament for the topical treatment of burns
AU3071899A (en) Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma
AU2001262520A1 (en) Combined preparation for the treatment of neoplasic diseases
AU2002214977A1 (en) Tetrahydrocarbazoles, a process for the preparation of those compounds, and the use thereof
AU2001274446A1 (en) Vip-related peptides for the treatment of skin disorders
AU2002348105A1 (en) Oral dosage forms for improving the bioavailability of therapeutic agents
AU4453301A (en) Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
IL150402A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF